Member Info for GoHigh

Good news ! Hopefully next RNS will be a very good one!

Janus Henderson Group PLC increases their stake to 5.04%

https://www.londonstockexchange.com/news-article/JUST/holding-s-in-company/16086602

Acuere

WH Ireland's 90p target is a welcome news!

MickR

Prudent analogy. Totally agree !

Definitely excellent news. Things have started to move quickly and in right rirections :)

TradingView showing a very pleasing target price: 175p (1246.15%)

TradingView target price: 175p (1246.15%)

Oxford, UK. GENinCode Plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease ("CVD"), announces it has filed its Premarket Notification (510k) with the Food and Drug Administration (FDA) to expand its US commercial distribution of the CARDIO inCode-Score ("CIC-SCORE") polygenic test for the risk assessment and prevention of Coronary Heart Disease ("CHD"). ...

RNS:

https://www.londonstockexchange.com/news-article/GENI/cardio-incode-510k-filing/16086287

TradingView showing target price: 175p (1246.15%)

Oxford, UK. GENinCode Plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease ("CVD"), announces it has filed its Premarket Notification (510k) with the Food and Drug Administration (FDA) to expand its US commercial distribution of the CARDIO inCode-Score ("CIC-SCORE") polygenic test for the risk assessment and prevention of Coronary Heart Disease ("CHD"). ...

RNS: https://www.londonstockexchange.com/news-article/GENI/cardio-incode-510k-filing/16086287

RNS OUT:

Premarket Notification 510(k) medical device filing for CARDIO inCode-Score (CIC-SCORE)

510(k) approval will enable US expansion and commercial distribution of CARDIO inCode-Score medical device

Oxford, UK. GENinCode Plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease ("CVD"), announces it has filed its Premarket Notification (510k) with the Food and Drug Administration (FDA) to expand its US commercial distribution of the CARDIO inCode-Score ("CIC-SCORE") polygenic test for the risk assessment and prevention of Coronary Heart Disease ("CHD"). ...

https://www.londonstockexchange.com/news-article/GENI/cardio-incode-510k-filing/16086287

Premarket Notification 510(k) medical device filing for CARDIO inCode-Score (CIC-SCORE)

510(k) approval will enable US expansion and commercial distribution of CARDIO inCode-Score medical device

RNS: https://www.londonstockexchange.com/news-article/GENI/cardio-incode-510k-filing/16086287

1p sounds a bit too optimistic at this time but mid/long term is quite plausible!

Shanta Gold takeover rumours help shares shine

By ALASTAIR FORD, PROACTIVE INVESTORS, FOR THISISMONEY.CO.UK

PUBLISHED: 13:23, 14 August 2023 | UPDATED: 10:32, 15 August 2023

Shanta Gold looks a potential takeover target after gold production from its Tanzanian mines hit an annualised 100,000 ounces per year.

...

https://www.thisismoney.co.uk/money/investing/article-12404761/SMALL-CAP-IDEA-Shanta-Gold-takeover-rumours-held-shares-shine.html

Hotfinance14

I don't know what is going on; although all test preperations are ready for several weeks. QED is usually very active with news/RNS releases so I thought nothing has taken place yet. These are complex tech. issues; so it is better done right even if it takes some extra time. I am more than happy to wait for a good outcome :)

AimHigherStill

Kat's question was: "Being cynical, if the licence was sol valuable how come it went for less than a £million?"

But, after reading the post from billy101203 I have a better understanding: "the licence is only any good if you have the platform to opperate from"

Hopefully tomorrow will be better!

Yes, buying has started.

Katstrangler

Sounds like a very practical question to me. Certainly NOT cynical ...

Shanta Gold (LSE:SHG) Price Target Increased by 6.25% to 26.01

August 03, 2023 — 10:08 pm EDT / Written by George Maybach for Fintel -> at www.nasdaq.com

The average one-year price target for Shanta Gold (LSE:SHG) has been revised to 26.01 / share. This is an increase of 6.25% from the prior estimate of 24.48 dated July 5, 2023.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 21.21 to a high of 31.50 / share. The average price target represents an increase of 152.52% from the latest reported closing price of 10.30 / share.

https://www.nasdaq.com/articles/shanta-gold-lse:shg-price-target-increased-by-6.25-to-26.01

From the RNS on June 22, 2023:

"Quadrise is pleased to announce that the necessary parts and spares have been delivered to Morocco. Our personnel have installed the parts, re-tested the fuel delivery system and are ready to recommence the trial at the next available opportunity."

Apparently they are yet to run the trial!

Perhaps it is time for some sort of update from Morocco !